Missouri Society of Health-System Pharmacists - Featured Clinical Topic: Infectious Diseases
Frontiers | Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of Clostridioides difficile | Microbiology
Breakthroughs in the treatment and prevention of Clostridium difficile infection | Nature Reviews Gastroenterology & Hepatology
Actoxumab/Bezlotoxumab
RCSB PDB - 4NP4: Clostridium difficile toxin B CROP domain in complex with FAB domains of neutralizing antibody bezlotoxumab
Structural basis of strain-specific differences in bezlotoxumab potency... | Download Scientific Diagram
PDB 4np4 structure summary ‹ Protein Data Bank in Europe (PDBe) ‹ EMBL-EBI
RCSB PDB - 4NP4: Clostridium difficile toxin B CROP domain in complex with FAB domains of neutralizing antibody bezlotoxumab
Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials
Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography - Journal of Biological Chemistry
Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota | Nature Communications
Bezlotoxumab for the prevention of Clostridium difficile inf | IDR
Frontiers | Clostridium difficile – From Colonization to Infection | Microbiology
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection | NEJM
Nonantimicrobial drug targets for Clostridium difficile infections | Future Microbiology
Mapping the binding sites for CSPG4, FZDs, and bezlotoxumab in TcdB... | Download Scientific Diagram
Therapeutic Antibodies to Track in 2017, Part I
Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection - Clinical Trials Arena
JCI Insight - Human C. difficile toxin–specific memory B cell repertoires encode poorly neutralizing antibodies
Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab - ScienceDirect
Bezlotoxumab Stories - Wattpad
Zinplava - FDA prescribing information, side effects and uses
Immune response against Clostridioides difficile and translation to therapy - Kanika Sehgal, Sahil Khanna, 2021
Figure 1 | Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies | SpringerLink
